What is the ticker symbol for Aclaris Therapeutics?

Aclaris Therapeutics trades under the ticker ACRS on NASDAQ.

What sector does Aclaris Therapeutics operate in?

Aclaris Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ACRS in a portfolio?

PortView shows ACRS's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

Aclaris Therapeutics (ACRS) Stock Analysis

NASDAQHealthcareBiotechnology

$3.86+1.72%

1-year price historyRange $2.13 – $6.54

52-week range$3.86

$2.10$6.60

Track ACRS in your portfolio for free · Portfolio tracker

What Aclaris Therapeutics does

Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.

Key metrics

Market cap

$567.45M

P/E (TTM)

-6.65

EPS (TTM)

$-0.58

Beta

0.80

Dividend yield

0.00%

Revenue / share

$0.06

50-day avg

$5.02

200-day avg

$4.51

52-week high

$6.60

52-week low

$2.10

CEO

Neal S. Walker

ETFs linked to ACRS

Broad-market and Healthcare sector ETFs an investor holding Aclaris Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how ACRS fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze ACRS in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for Aclaris Therapeutics?: Aclaris Therapeutics trades under the ticker ACRS on NASDAQ.
Which exchange is ACRS listed on?: ACRS is listed on NASDAQ.
What sector does Aclaris Therapeutics operate in?: Aclaris Therapeutics is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze ACRS in a portfolio?: PortView shows ACRS's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.